Company to present an update of its ongoing monotherapy and combination Phase 1/1b study of WTX-124 in advanced or metastatic solid tumors April 24, 2024 -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that an abstract providing an update of the Company’s ongoing mono

Flindr Therapeutics今天宣布完成2000万欧元的A轮融资，以推进其潜在“first-in-class”小分子癌症疗法。 这次融资由V-Bio Ventures领投，其他新投资者包括强生创新（JJDC）、QBIC Fund、Flanders Future Tech Fund和Curie Capital，以及现有投资者Oncode Oncology Bridge Fund、Swanbridge和Brabantse Ontwikkelings Maatschappij（BOM）参投。 Flindr通过其“ImmunoGram药物发现引擎”进行药物开发，该引擎源自荷兰癌症研究所（NKI）和Oncode研究所的开创性工作。该方法将临床患者中常见的肿瘤和宿主特异性因素的异质性反向转化成实验室生物模型，并通过此模型筛选和选择与患者临床应答有关的重要药物靶点。 Flindr的主打项目是一款潜在"first-in-class"的RNF31（也称为HOIP）靶向小分子抑制剂，RNF31是一种协助蛋白质稳定的E3泛素连接酶，在实体瘤和血液恶性肿瘤中异常激活。该公司已在临床前卵巢癌和B细胞淋

Oral presentation will feature new data for investigational REGN7075, an EGFRxCD28 costimulatory bispecific with the potential to enhance the treatment of certain advanced solid tumors in combination with Libtayo® (cemiplimab-rwlc) 17 presentations to highlight Regeneron's investigational pipeline including checkpoint inhibitors, CD3 bispecifics and CD28 costimulatory bispecifics April 24, 2024 -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new and updated data from its oncol

Poster presentation scheduled for June 1, 2024, 1:30-4:30 PM CT /2:30-5:30 PM ET Trial being led by Georgetown University’s Lombardi Comprehensive Cancer Center April 24, 2024 -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that a late-breaking abstract with preliminary findings from the Phase 2 investigator-sponsored trial of BXCL701 in combinati

- $240 million private placement financing led by RA Capital Management with significant participation by Bain Capital Life Sciences as well as BVF Partners and Canaan Partners to fund Phase 2b clinical trial - CD388, which is active against all strains of influenza A and B, is being developed for pre-exposure prophylactic treatment - Company to host business strategy update conference call and webcast today at 4:30 PM ET April 24, 2024 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnol

Endeavor BioMedicines今天宣布成功完成了1.325亿美元的C轮融资。获得的资金将用于推动其主打在研疗法ENV-101的临床开发，这款小分子疗法旨在治疗特发性肺纤维化（IPF）和进行性肺纤维化（PPF）。此外，这笔资金还将支持ENV-501的临床概念验证研究，ENV-501是一种针对人表皮生长因子3（HER3）阳性实体瘤的抗体偶联药物（ADC）。 本轮融资由Matrix Capital Management旗下的AyurMaya领投。新投资者包括Fidelity Management & Research Company、Invus、SymBiosis、Velosity Capital和Woodline Partners。现有投资者包括abrdn管理的基金、Ally Bridge Group、Avidity Partners、Eckuity Capital、Longitude Capital、Omega Funds、Perceptive Advisors、Piper Heartland Healthcare Capital、Silver Arch Bio和T. Row

First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation RAPNO LGG overall response rate (ORR) of 51% Day One receives rare pediatric disease priority review voucher Conference call and webcast to be April 24, 8:30 a.m. Eastern Time April 23, 2024 -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceutical company dedicated to developin

GSK has selected the first two programs to advance following achievement of target validation, marking transition to next phase of research collaboration; programs utilize Wave’s next generation GalNAc-siRNA format with potential for best-in-class potency and durability GSK collaboration continues to span all Wave modalities, including RNA editing, with target validation ongoing in multiple therapy areas Wave is on track to initiate a clinical trial of its wholly owned INHBE program for obesity

4月23日，熙源安健宣布完成超亿元Pre-A和Pre-A+融资。熙源安健是一家专注于疼痛管理领域创新性治疗药物开发的生物医药公司，本轮所融资金将用于其产品管线在临床前和临床阶段的开发，特别是加速其自主研发并进入临床的CGRP类小分子药物BR005项目的临床试验进度。 熙源安健专注于开发针对严重慢性疼痛病症的创新型、高特异性的镇痛疗法，尤其重视解决头面部疼痛、肌肉骨骼疼痛和神经性疼痛等临床长期未满足需求。该公司的愿景是为全球众多饱受慢痛折磨的患者提供安全、有效、便捷的疼痛管理解决方案。熙源安健目前已有两款药物进入临床阶段。 其中，BR005是由熙源安健研发的小分子CGRP受体拮抗剂。BR005可通过选择性结合CGRP受体以抑制该通路的生物学活性，从而发挥治疗作用，缓解偏头痛急性发作时的症状。该产品已经在中国获批临床，拟用于治疗成人有先兆或无先兆急性偏头痛，目前1期临床研究已完成首例受试者入组。 另一款在研产品BR01T为一款TrkA抗体，拟开发用于治疗慢性下腰痛。该产品通过选择性地影响关键疼痛信号传导通路，为患者提供疼痛缓解效果，同时避免可能出现的骨相关副作用。BR01T通过在急性和慢性

4月24日，中国国家药品监督管理局药品审评中心（CDE）官网显示，康方生物自主研发的PD-1/CTLA-4双特异性抗体卡度尼利单抗注射液的一项新适应症上市申请获得受理。根据康方生物新闻稿，这是卡度尼利的第3个适应症上市申请，拟加含铂化疗联合/不联合贝伐珠单抗对比安慰剂加含铂化疗联合/不联合贝伐珠单抗用于一线治疗持续、复发或转移性宫颈癌。 卡度尼利单抗是康方生物自主研发的一款PD-1/CTLA-4双特异性肿瘤免疫治疗药物。2022年6月，卡度尼利已获得中国NMPA批准上市，单药治疗既往接受含铂化疗治疗失败的复发或转移性宫颈癌。2024年1月，卡度尼利联合标准治疗方案一线治疗晚期胃癌的新适应症上市申请也已获CDE受理。 此次卡度尼利方案一线治疗晚期宫颈癌新适应症上市申请获得受理是基于AK104-303研究。AK104-303研究是PD-1/CTLA-4双特异性抗体卡度尼利加含铂化疗联合/不联合贝伐珠单抗用于一线治疗持续、复发或转移性宫颈癌的随机、双盲对照的3期临床研究。主要研究终点为独立中心影像评估（BICR）基于 RECIST v1.1评估的无进展生存期（PFS）和总生存期（OS）。 据